• A federal court ruling found Liquidia (NASDAQ: LQDA)'s lead product, YUTREPIA, infringed on patents held by United Therapeutics, specifically concerning its use for PH-ILD.
  • Following the adverse ruling, Liquidia's shares experienced a significant sell-off, dropping by as much as 57%, impacting its year-to-date performance.
  • The patent dispute introduces considerable uncertainty regarding YUTREPIA's commercial outlook and potential sales, despite a prior $30 price target from Wells Fargo.

The biotech stock of Liquidia (NASDAQ: LQDA), a drug company, is currently under pressure. Its lead product, YUTREPIA, is an inhaled pulmonary hypertension treatment. United Therapeutics is a rival in this market. Wells Fargo previously set a $30 price target for Liquidia, compared with a share price of $27.99. That implied a potential gain of $2.01 per share, or about 7.2%.

That target depends in part on YUTREPIA’s commercial outlook, which now faces a significant patent dispute. A federal court in Delaware ruled that two patent claims held by United Therapeutics are valid and infringed by YUTREPIA. The claims specifically concern the treatment of pulmonary hypertension associated with interstitial lung disease, known as PH-ILD.

Liquidia plans to remove the PH-ILD use from YUTREPIA’s label, which could reduce the number of patients it can reach. United Therapeutics seeks an injunction, while Liquidia plans to appeal the decision. The parties must also propose a remedy for the court to consider, leaving the final effect on sales and the drug development company's future uncertain.

The ruling significantly weighs on Liquidia's stock performance. Shares fell 57%, as highlighted by Zacks, while Reuters reports a drop of nearly 50% on Wednesday. These figures reflect separate accounts of the sell-off. Following the decline, Liquidia is down 12.2% for the year, compared with a 7.7% gain for its industry.

At the quoted price of $27.99, Liquidia is down $2.27, or 7.50%, for the session. Its 52-week range is $21.35 to $93.61. The gap between the current price and Wells Fargo’s $30 target is narrow, while the court ruling creates uncertainty around the sales YUTREPIA can generate, impacting the overall investment outlook for Liquidia.